BIO-TECHNE DECLARES DIVIDEND
Rhea-AI Summary
Catcher Investments acquired 3,000 unsecured convertible debentures of Optimi Health Corp on July 25, 2025, for a total of CAD 3,000,000 in a non-brokered private placement.
The debentures bear 15.0% annual interest payable quarterly, mature in 12 months (extendable to 24 months at the acquiror's option), and are convertible into common shares at a conversion price of CAD 0.15. Accrued interest may be paid in cash or common shares (issued at the most recent CSE closing price if converted).
Before and after the investment the acquiror directly or indirectly holds 8,237,501 common shares (~8.52% undiluted) and, including warrants and options, represents ~10.08% on a partially diluted basis.
Positive
- Raised CAD 3,000,000 via 3,000 convertible debentures
- Debentures carry 15.0% annual interest payable quarterly
- Conversion price fixed at CAD 0.15 per share
- Acquiror stake equals ~10.08% on partial dilution
Negative
- Potential equity dilution if debentures or accrued interest convert
- Issuer faces 15.0% annual cash interest obligation
- Short 12-month maturity (extendable to 24 months) creates near-term refinancing risk
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over
Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.
|
Contact: |
David Clair, Vice President, Investor Relations & Corporate Development |
|
|
|
|
|
612-656-4416 |
FAQ
What did Catcher Investments acquire from Optimi Health on July 25, 2025?
What are the key terms of the Optimi Health debentures issued July 25, 2025?
How could the July 25, 2025 debenture deal affect Optimi Health shareholders?
What stake does Catcher Investments hold in Optimi Health after the July 25, 2025 transaction?
Can accrued interest on the Optimi debentures be paid in shares?
